Proteomics-based prediction of clinical response in acute myeloid leukemia.

[1]  S. Hanash,et al.  Mining the plasma proteome for cancer biomarkers , 2008, Nature.

[2]  Gil Alterovitz,et al.  Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease , 2007, Proceedings of the National Academy of Sciences.

[3]  F. Grall,et al.  Perspectives of proteomics in acute myeloid leukemia , 2006, Expert review of anticancer therapy.

[4]  E. Estey,et al.  Proteomic‐based prediction of clinical behavior in adult acute lymphoblastic leukemia , 2006, Cancer.

[5]  T. Veenstra,et al.  Enrichment of low-molecular-weight proteins from biofluids for biomarker discovery , 2005, Expert review of proteomics.

[6]  A. Zipursky,et al.  Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome , 2004, Leukemia.

[7]  L. Rassenti,et al.  Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti‐CD52 antibodies , 2004, Cancer.

[8]  J. Wiemer,et al.  Bioinformatics in proteomics: application, terminology, and pitfalls. , 2004, Pathology, research and practice.

[9]  E. Estey,et al.  Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. , 2004, Blood.

[10]  T. Veenstra,et al.  The Human Plasma Proteome , 2004, Molecular & Cellular Proteomics.

[11]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Armitage,et al.  Circulating CD20 and CD52 in patients with non‐Hodgkin's lymphoma or Hodgkin's disease , 2003, British journal of haematology.

[13]  K. Do,et al.  Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. , 2003, Blood.

[14]  David E. Misek,et al.  Discordant Protein and mRNA Expression in Lung Adenocarcinomas * , 2002, Molecular & Cellular Proteomics.

[15]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[16]  Thomas Deufel,et al.  Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. , 2007, Clinical chemistry and laboratory medicine.

[17]  E. Estey,et al.  Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias , 2005, Leukemia.

[18]  M. Caligiuri,et al.  Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA , 2003, Leukemia.